Interview: Celltrion's Journey To The Top

In just 15 years since its establishment, Celltrion has transformed from a modest contract manufacturer in South Korea into a global leader in antibody biosimilars. In this instalment of Scrip’s Leadership Series, CEO Woo Sung Kee talks about what it has taken for the company and its top management to achieve such rapid growth, its ambitions to enter the global top 10 biotech firms, and his own work philosophy.

"An insight into the future. Many people can have this, but not everyone can materialize this."

So says Celltrion Inc. president and CEO Woo Sung Kee of the company’s founder and chairman Jung Jin Seo....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

A MoonLake Buyout Would Boost Merck & Co’s Immunology Ambitions

05 Jun 2025

• By Andrew McConaghie

As the patent protection clock ticks down on Merck’s flagship blockbuster Keytruda, the company is reported to be pursuing the inflammation and immunology biotech. Such a move would bulk up its sparse I&I pipeline.

Europe’s Drugmakers Lament EU Pharma Package

05 Jun 2025

• By Kevin Grogan

EFPIA says reforms make the continent less attractive for innovative firms.

Deal Watch: Lilly Licenses Camurus’s Delivery Technology For Long-Acting Incretins

04 Jun 2025

• By Joseph Haas

Plus deals involving Roche/Vividion, Alto/Chase, Biogen/City Therapeutics, Sanofi/Nurix and Naya/Invo.

Finance Watch: Is Six The Magic Number? May Sees Half Dozen VC Mega-Rounds

04 Jun 2025

• By Mandy Jackson

Private Company Edition: Six biopharma companies raised venture capital rounds totaling $100m or more in May, matching the number of mega-rounds in April and March. Among other recent financings, Syndeio launched with $90m and SpyGlass raised a $75m series D round.

ASCO: Carvykti Data Raise Possibility Of Myeloma Cure

04 Jun 2025

• By Alaric DeArment

J&J presented data at the American Society of Clinical Oncology meeting showing more than five-year disease- and therapy-free survival, but a myeloma working group will need to define what makes a cure.